Literature DB >> 18558995

FLIP ing the coin? Death receptor-mediated signals during skin tumorigenesis.

Martin Leverkus1, Philip Diessenbacher, Peter Geserick.   

Abstract

Keratinocyte skin cancer is a multi-step process, during which a number of obstacles have to be overcome by the tumor cell to allow the development of a manifest tumor. Beside proliferation and immortality, apoptosis resistance is one additional and critical step during skin carcinogenesis. Over the past two decades, much has been learned about the prototypical membrane-bound inducers of apoptosis, namely the death receptors and their ligands, and the apoptosis signalling pathways activated by death receptors have been elucidated in great detail. In contrast, much less is known about the tissue-specific role of the death receptor/ligands systems during the development of skin cancer. Here, we summarize and discuss the role of this intriguing receptor family and the potential mechanistical impact of the intracellular caspase-8 inhibitor cFLIP for keratinocyte skin cancer. Given more recent data about cFLIP and its isoforms, a more complex regulatory role of cFLIP can be suspected. Indeed, cFLIP may not solely interfere with death receptor-mediated apoptosis signalling pathways, but may positively or negatively influence other, potential harmful signalling pathways such as the production of inflammatory cytokines, tumor cell migration or the activation of transcription factors such as NF-kappaB, considered crucial during skin tumorigenesis. In this respect, cFLIP may act to 'FLIP the coin' during the development of keratinocyte skin cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18558995     DOI: 10.1111/j.1600-0625.2008.00728.x

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  9 in total

1.  Bcl-2 expression indicates better prognosis of Merkel cell carcinoma regardless of the presence of Merkel cell polyomavirus.

Authors:  Helka Sahi; Virve Koljonen; Heli Kavola; Caj Haglund; Erkki Tukiainen; Harri Sihto; Tom Böhling
Journal:  Virchows Arch       Date:  2012-09-14       Impact factor: 4.064

2.  Cellular FLICE-inhibitory protein (cFLIP) isoforms block CD95- and TRAIL death receptor-induced gene induction irrespective of processing of caspase-8 or cFLIP in the death-inducing signaling complex.

Authors:  Shyam M Kavuri; Peter Geserick; Daniela Berg; Diana Panayotova Dimitrova; Maria Feoktistova; Daniela Siegmund; Harald Gollnick; Manfred Neumann; Harald Wajant; Martin Leverkus
Journal:  J Biol Chem       Date:  2011-03-22       Impact factor: 5.157

Review 3.  Molecular signaling cascades involved in nonmelanoma skin carcinogenesis.

Authors:  Robert P Feehan; Lisa M Shantz
Journal:  Biochem J       Date:  2016-10-01       Impact factor: 3.857

4.  Targeting the Anti-Apoptotic Protein c-FLIP for Cancer Therapy.

Authors:  Ahmad R Safa; Karen E Pollok
Journal:  Cancers (Basel)       Date:  2011-06       Impact factor: 6.639

5.  Roles of c-FLIP in Apoptosis, Necroptosis, and Autophagy.

Authors:  Ahmad R Safa
Journal:  J Carcinog Mutagen       Date:  2013

6.  Immunohistopathological Study of c-FLIP Protein in Mycosis Fungoides

Authors:  Ghada Fawzy Rezk Hassan; Karima Marey
Journal:  Asian Pac J Cancer Prev       Date:  2017-09-27

7.  Cellular IAPs inhibit a cryptic CD95-induced cell death by limiting RIP1 kinase recruitment.

Authors:  Peter Geserick; Mike Hupe; Maryline Moulin; W Wei-Lynn Wong; Maria Feoktistova; Beate Kellert; Harald Gollnick; John Silke; Martin Leverkus
Journal:  J Cell Biol       Date:  2009-12-28       Impact factor: 10.539

8.  The ratio of Mcl-1 and Noxa determines ABT737 resistance in squamous cell carcinoma of the skin.

Authors:  P Geserick; J Wang; M Feoktistova; M Leverkus
Journal:  Cell Death Dis       Date:  2014-09-11       Impact factor: 8.469

9.  The contact allergen nickel sensitizes primary human endothelial cells and keratinocytes to TRAIL-mediated apoptosis.

Authors:  Marc Schmidt; Mike Hupe; Nicole Endres; Badrinarayanan Raghavan; Shyam Kavuri; Peter Geserick; Matthias Goebeler; Martin Leverkus
Journal:  J Cell Mol Med       Date:  2009-06-16       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.